<DOC>
	<DOC>NCT00670215</DOC>
	<brief_summary>The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biopsies of the prostate (TRNBP).</brief_summary>
	<brief_title>BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Transrectal needle biopsy of the prostate required. A cleancatch midstreamurine (MSU) culture negative (&lt;104 CFU/mL) for possible pathogens at the PreTherapy Visit prior to the TRNBP. Gastrointestinal absorption is adequate as evidenced by passage of gas or feces per rectum and patient can tolerate oral food, fluids, and medication without vomiting or diarrhea. History of hypersensitivity to ciprofloxacin or other quinolone antibiotics Valvular heart disease that requires antibiotic prophylaxis to prevent bacterial endocarditis Concomitant use of theophylline, probenecid, or warfarin at any time during the entire study Renal insufficiency Known or suspected central nervous system disorder that may predispose to seizures or lower the seizure threshold Absolute neutrophil count (ANC) &lt;1000/mm3 Human immunodeficiency virus (HIV) infection with a CD4 count &lt;200 cells/micL. HIV testing is NOT required Antibiotic administration within one week of the TRNBP Severe hepatic insufficiency (ChildPugh C)</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Prevention of infectious complications</keyword>
	<keyword>transrectal needle biopsies of the prostate</keyword>
	<keyword>TRNBP</keyword>
</DOC>